Barclays Downgrades Sandoz Group (OTCMKTS:SDZNY) to Hold

Sandoz Group (OTCMKTS:SDZNY) was downgraded by stock analysts at Barclays from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

Separately, Jefferies Financial Group raised shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy”.

Sandoz Group Trading Down 2.9%

OTCMKTS:SDZNY opened at $88.02 on Thursday. The company has a current ratio of 1.29, a quick ratio of 0.82 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $79.44 and its 200 day simple moving average is $69.53. Sandoz Group has a twelve month low of $35.61 and a twelve month high of $94.15.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.